Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 11.13%410.3B | 1.57%1.45T | 3.76%360.35B | 0.78%367.89B | -1.42%347.96B | 3.22%369.19B | 13.02%1.42T | 3.17%347.31B | 12.48%365.06B | 16.26%352.97B |
Cost of revenue | 9.06%363.01B | 9.07%1.28T | -2.41%315.59B | 8.91%335.11B | 6.13%295.71B | 26.46%332.85B | 17.14%1.17T | 24.51%323.37B | 19.09%307.69B | 13.98%278.63B |
Gross profit | 30.12%47.29B | -33.57%166.13B | 87.01%44.76B | -42.85%32.79B | -29.72%52.24B | -61.53%36.34B | -2.98%250.11B | -68.88%23.93B | -13.32%57.37B | 25.67%74.34B |
Operating expense | 4.51%17.31B | 5.70%67.65B | -0.06%17.63B | 8.12%16.34B | 1.85%17.12B | 14.71%16.56B | 21.41%64B | 20.85%17.64B | 18.23%15.11B | 24.21%16.81B |
Selling and administrative expenses | 4.51%17.31B | 5.70%67.65B | -0.06%17.63B | 8.12%16.34B | 1.85%17.12B | 14.71%16.56B | 21.41%64B | 20.85%17.64B | 18.23%15.11B | 24.21%16.81B |
-General and administrative expense | 4.51%17.31B | 5.70%67.65B | -0.06%17.63B | 8.12%16.34B | 1.85%17.12B | 14.71%16.56B | 21.41%64B | 20.85%17.64B | 18.23%15.11B | 24.21%16.81B |
Operating profit | 51.55%29.98B | -47.08%98.49B | 331.22%27.13B | -61.07%16.45B | -38.95%35.13B | -75.28%19.78B | -9.25%186.11B | -89.90%6.29B | -20.87%42.26B | 26.10%57.53B |
Net non-operating interest income (expenses) | 257.80%16.06B | -97.48%524M | 99,350.00%1.99B | 44.89%-6.01B | -98.96%63M | -82.49%4.49B | -28.09%20.79B | -100.01%-2M | -304.71%-10.91B | 92.67%6.08B |
Non-operating interest income | 193.43%23.37B | -35.97%18.82B | 307.84%8.74B | ---- | -56.92%4.19B | -70.54%7.97B | -7.83%29.39B | -88.37%2.14B | ---- | 203.05%9.73B |
Non-operating interest expense | 110.35%7.31B | 112.83%18.3B | 214.88%6.75B | -44.89%6.01B | 13.07%4.13B | 147.30%3.48B | 189.53%8.6B | 12,011.11%2.14B | 957.07%10.91B | 6,417.86%3.65B |
Net investment income | ||||||||||
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | -116.21%-2.26B | -9.36%33.12B | -86.10%1.63B | 198.40%15.3B | -69.73%2.24B | 13.72%13.94B | -36.50%36.54B | -29.10%11.74B | -69.00%5.13B | -47.33%7.4B |
Special income (charges) | ||||||||||
Other non-operating income (expenses) | -18.12%-13.09B | -168.57%-36.33B | -230.37%-22.31B | -39.89%7.84B | -81.41%-10.78B | 20.15%-11.08B | -120.53%-13.53B | -110.43%-6.75B | 933.67%13.05B | -438.41%-5.94B |
Income before tax | 13.10%30.69B | -58.33%95.8B | -25.21%8.44B | -32.19%33.58B | -59.05%26.65B | -73.92%27.13B | -35.68%229.91B | -93.04%11.28B | -32.81%49.52B | 5.41%65.07B |
Income tax | 125.79%9.22B | -41.16%34.99B | 402.31%8.47B | -10.62%12.66B | -53.34%9.78B | -81.98%4.08B | 0.96%59.47B | -96.21%1.69B | 8.96%14.16B | 268.09%20.96B |
Net income | -6.86%21.47B | -64.33%60.8B | -100.40%-38M | -40.83%20.92B | -61.76%16.87B | -71.68%23.05B | -42.91%170.44B | -91.84%9.59B | -41.75%35.36B | -40.55%44.11B |
Net income continuous operations | -6.86%21.47B | -64.33%60.8B | -100.40%-38M | -40.83%20.92B | -61.76%16.87B | -71.68%23.05B | -42.91%170.44B | -91.84%9.59B | -41.75%35.36B | -40.55%44.11B |
Noncontrolling interests | -126.14%-606M | -77.66%2.2B | -117.48%-313M | -72.56%450M | -116.79%-253M | -52.87%2.32B | -43.66%9.86B | -73.00%1.79B | -63.25%1.64B | -55.96%1.51B |
Net income attributable to the company | 6.48%22.08B | -63.51%58.6B | -96.48%275M | -39.29%20.47B | -59.81%17.12B | -72.88%20.73B | -42.86%160.59B | -92.97%7.8B | -40.05%33.72B | -39.81%42.6B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 6.48%22.08B | -63.51%58.6B | -96.48%275M | -39.29%20.47B | -59.81%17.12B | -72.88%20.73B | -42.86%160.59B | -92.97%7.8B | -40.05%33.72B | -39.81%42.6B |
Gross dividend payment | ||||||||||
Basic earnings per share | 6.48%80.34 | -63.51%213.28 | -96.48%1 | -39.29%74.52 | -59.81%62.31 | -72.89%75.45 | -42.86%584.44 | -92.97%28.4 | -40.04%122.74 | -39.81%155.04 |
Diluted earnings per share | 6.48%80.34 | -63.51%213.28 | -96.48%1 | -39.29%74.52 | -59.81%62.31 | -72.89%75.45 | -42.86%584.44 | -92.97%28.4 | -40.04%122.74 | -39.81%155.04 |
Dividend per share | 0 | -52.20%98 | -45.22%63 | 0 | -61.11%35 | 0 | -31.89%205 | -38.83%115 | 0 | -20.35%90 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |